Kinam Hong

Kinam joined Sofinnova Partners in January 2017. Kinam co-managed the Exane Equinox fund, a global healthcare fund with a focus on later-stage, public biotechnology companies. Kinam invested in global life sciences companies developing innovative medicines with the potential to address areas of large unmet medical need. Kinam had previously spent 10 years as an investor and analyst covering the biotechnology sector, including at Citigroup investment research where he focused on small- and mid-cap biotechnology companies.

Prior to his investment career, Kinam worked in new product development at Sanofi, a multi-national pharmaceutical company, where he managed a HIV vaccine candidate in Phase 3 development. Kinam also held roles in business development and strategic marketing, where he worked on various infectious diseases and oncology licensing deals and on Sanofi’s strategy in China, respectively.

Kinam is a medical doctor and holds degrees in molecular biology/biochemistry and medicine from the University of Florida. He also holds a CFA (Chartered Financial Analyst) and MBA from INSEAD (France).